Sophiris Bio, Inc.
(NASDAQ : SPHS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
VTLVital Therapies, Inc.
1.50%13.513.3%$792.68m
AMGNAmgen Inc.
2.36%204.021.3%$749.47m
GILDGilead Sciences, Inc.
0.43%63.140.9%$384.23m
CELGCelgene Corporation
1.53%94.741.3%$360.74m
ILMNIllumina, Inc.
0.49%286.173.5%$321.19m
BIIBBiogen Inc.
1.78%231.681.3%$305.34m
VRTXVertex Pharmaceuticals Incorporated
2.11%184.941.9%$260.38m
EXASExact Sciences Corporation
1.35%119.8224.1%$245.81m
ALXNAlexion Pharmaceuticals, Inc.
1.66%110.852.0%$238.74m
REGNRegeneron Pharmaceuticals, Inc.
1.28%296.852.6%$212.35m
AAgilent Technologies, Inc.
2.18%71.111.6%$206.33m
SRPTSarepta Therapeutics, Inc.
2.44%124.9514.7%$156.17m
INCYIncyte Corporation
3.11%83.122.5%$97.22m
BMRNBioMarin Pharmaceutical Inc.
6.65%76.504.3%$91.98m
SGENSeattle Genetics, Inc.
3.25%79.206.5%$90.21m

Company Profile

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The firm develops PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.